RT Journal Article
SR Electronic
T1 Immunological characteristics govern the changing severity of COVID-19 during the transition to endemicity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.03.20187856
DO 10.1101/2020.09.03.20187856
A1 Lavine, Jennie S
A1 Bjornstad, Ottar N
A1 Antia, Rustom
YR 2020
UL http://medrxiv.org/content/early/2020/09/05/2020.09.03.20187856.abstract
AB As prospects for eradicating CoV-2 dwindle, we are faced with the question of how the severity of CoV-2 disease may change in the years ahead. Will CoV-2 continue to be a pathogenic scourge that, like smallpox or measles, can be tamed only by ongoing vaccination, or will it join the ranks of mild endemic human coronaviruses (HCoVs)? Our analysis of immunological and epidemiological data on HCoVs shows that infection-blocking immunity wanes rapidly, but disease-reducing immunity is long-lived. We estimate the relevant parameters and incorporate them into a new epidemiological model framework which separates these different components of immunity. Our model recapitulates both the current severity of CoV-2 and the relatively benign nature of HCoVs; suggesting that once the endemic phase is reached, CoV-2 may be no more virulent than the common cold. The benign outcome at the endemic phase is contingent on the virus causing primary infections in children. We predict a very different outcome were a CoV like MERS (that causes severe disease in children) to become endemic. These results force us to re-evaluate control measures that rely on identifying and isolating symptomatic infections, and reconsider ideas regarding herd immunity and the use of immune individuals as shields to protect vulnerable groups.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNIHAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Analysis involves data from literatureAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnalysis involves data from literature. It is available in the supplementary information